Ginkgo biloba in patients with decreasing mental performance, peripheral arterial occlusive disease, vertigo or tinnitus.

Ginkgo biloba, an herbal medicinal product, is thought to reduce inflammation, improve cerebral blood flow and exert antioxidant and neuroprotective effects. In Switzerland, ginkgo-based medicinal products are approved and reimbursed for adults with mental performance deficits, peripheral arterial occlusive disease, vertigo, and tinnitus. However, evidence on its clinical effectiveness is inconsistent in the literature. The aim of the HTA is to evaluate the efficacy, effectiveness, safety, cost-effectiveness and budget-impact of ginkgo biloba compared to placebo, no treatment or standard of care/active treatment.

Federal Office of Public Health FOPH

Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
Switzerland - 3003 Bern